Showing 1241-1250 of 20877 results for "".
- Gaps Between Expectations and Reality for an Intraoperative AI Interventionhttps://reachmd.com/news/gaps-between-expectations-and-reality-for-an-intraoperative-ai-intervention/2486054/A recent article conducted a multisite qualitative implementation assessment of the Operating Room Black Box, focusing on gaps between what surgeons expected an intraoper
- Perioperative Considerations and Cellular Immunotherapy Developments in Breast Cancerhttps://reachmd.com/news/perioperative-considerations-and-cellular-immunotherapy-developments-in-breast-cancer/2486060/A recent review summarizes evidence for immune checkpoint inhibitors (ICIs) in breast cancer, highlighting the most consistent clinical benefit in triple-negative breast cancer (TNBC), particularly with chemotherapy, alongside discussion of resistance mechanisms, translational biomarkers, a
- NFAT-Driven uNK Residency Switch Linked to Implantation and Preeclampsiahttps://reachmd.com/news/nfat-driven-unk-residency-switch-linked-to-implantation-and-preeclampsia/2486059/Investigators recently reported on an NFAT-driven “residency” switch in uterine natural killer (uNK) cells, framing NFAT signaling as a regulator of whether these cells adopt and
- Animal Models for Swine Influenza: Model Roles, Limits, and Surveillance Implicationshttps://reachmd.com/news/animal-models-for-swine-influenza-model-roles-limits-and-surveillance-implications/2486032/A recent review of swine influenza animal models describes how experimental readouts can shift depending on whether studies are conducted in mice, ferrets, guinea pigs, pigs, or non-human primate
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://reachmd.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- IL‑2–Armored FLT3 CAR‑γδT Cells: Preclinical Efficacy and Translational Signalshttps://reachmd.com/news/il2armored-flt3-cart-cells-preclinical-efficacy-and-translational-signals/2486036/Investigators report a preclinical evaluation of FLT3-targeted CAR-γδT cells “armored” to co-express IL-2 or IL-7 in acute myeloid leukemia (AML) models. The study describes three engineered prod
- Comparative Outcomes of Fluticasone‑Based vs Budesonide Dual Inhalers in COPDhttps://reachmd.com/news/comparative-outcomes-of-fluticasonebased-vs-budesonide-dual-inhalers-in-copd/2486037/Investigators reported comparative outcomes among US adults aged 40 years or older with chronic obstructive pulmonary disease (COPD) who initiated one of three inhaled corticosteroid–long-acting β-agonist (ICS–LABA) single-inhaler products in
- INTEGUMENT-OLE Data Show Sustained Efficacy of Roflumilast in Early Childhood ADhttps://reachmd.com/news/integument-ole-data-show-sustained-efficacy-of-roflumilast-in-early-childhood-ad/2486045/The 56-week phase 3 open-label extension for the INTEGUMENT trial (INTEGUMETN-OLE) indicated once-daily roflumilast cream 0.05% maintained efficacy and demonstrated favorable long-term safety in children aged 2 to 5 years with mild-to-moderate atopic dermatitis (AD
- First-week Hyperglycemia in Extremely Preterm Infantshttps://reachmd.com/news/first-week-hyperglycemia-in-extremely-preterm-infants-propensity-matched-cohort-findings/2486010/In extremely preterm infants, does first-week neonatal hyperglycemia identify a group with different short-term respiratory and ophthalmologic outcomes? Investigators at a single NICU reported a
- Integrated MALDI‑TOF MS and WGS in a Prolonged ICU Pseudomonas Outbreakhttps://reachmd.com/news/integrated-malditof-ms-and-wgs-in-a-prolonged-icu-pseudomonas-outbreak/2486016/In a prolonged intensive care unit (ICU) outbreak investigation of Pseudomonas aeruginosa, authors report using an integrated laboratory approach that combined phenotypic antimicrobial testing,